NCT06364917

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2025-05-30Est. Completion: 2027-04-27

Enrollment target: 24 participants

Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States

Contact

Aakash Desai, MD, MPHaakashdesai@uabmc.edu (205) 934-3411

Margaret Thomas, MPHmargaretannthomas@uabmc.edu

Other microbiome trials you might be interested in

A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)Phase 2Recruiting

Non-small Cell Lung Cancer

This trial is a registrational Phase II/III, randomized, open-label, multicenter study to evaluate the efficacy and safe…

Shanghai, ChinaEst. completion Dec 2032

View Trial →

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerPhase 3Recruiting

Recurrent Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Unresectable Lung Non-Small Cell Carcinoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.